Kinepolis still looks undervalued to me at €29.80. The market is pricing the company as if the recovery story remains fragile, but the underlying numbers are now stronger than that share price implies. In 2025, Kinepolis generated €564.9 million in revenue, €162.6 million in adjusted EBITDA, €37.9 million in net profit and €70.4 million in free cash flow. Net financial debt excluding leases fell to €287.2 million, while the proposed dividend was restored to €0.65 per share. Those are not the numbers of a business that is still fighting for stability. They are the numbers of a business that is rebuilding earnings power and cash generation in a visible way.
What makes the setup more interesting is that the near-term momentum also improved. In Q1 2026, Kinepolis reported a 27.4% increase in visitors, helped by a stronger film slate and the contribution from the Emagine acquisition in the U.S. That matters because the equity story now has both elements the market usually wants to see: improving fundamentals and improving sentiment. The company is no longer only talking about recovery; it is starting to show it in the operating numbers.
On valuation, the discount still looks too wide. Based on company-reported consensus figures, the market is looking for €59.9 million of net profit in 2026 and €70.6 million in 2027, with adjusted EBITDA rising to €203.6 million and €216.2 million respectively. At the current share price, that puts Kinepolis on roughly 13.6x 2026 earnings and 11.6x 2027 earnings, while the 2025 free cash flow yield is about 8.6%. For a business with strong market positions, premium formats, improving attendance and a clear deleveraging path, that does not look demanding.
My base-case view is that fair value sits meaningfully above the current price. I get to an adjusted base intrinsic value of around €41.28 per share, which implies that the stock is trading at roughly a 28% discount to what I would consider a reasonable fundamental value today. That does not mean the stock should trade there immediately. In the next 6 months, I would expect only partial convergence, which is why a move toward roughly €33 feels more realistic than an instant rerating to full fair value. Over 12 months, assuming continued delivery and no disruption in the box office slate, I think €38 is a credible base-case target. Over 24 months, if earnings normalize further and leverage continues to fall, I see a path toward €43.
The bull case is not hard to understand either. If the recovery proves durable, if Emagine integrates well, and if the market starts valuing Kinepolis on more normalized earnings rather than on lingering sector skepticism, I can see the shares moving to €46 over 12 months and €54 over 24 months. The bear case is equally clear: if the recovery stalls, the film slate disappoints, or U.S. integration becomes messier than expected, the stock could still drift back toward €25 or even €24. That is why I would not present this as risk-free. Cinema remains cyclical, and Kinepolis is still exposed to attendance volatility and consumer spending trends.
Still, the balance of probabilities looks attractive. At €29.80, the market seems to be pricing in more doubt than the current fundamentals justify. Kinepolis is not a flawless compounder, and it does not deserve a premium valuation without proof. But it also no longer looks like a business that should trade at a depressed recovery multiple. With free cash flow back, debt moving lower, earnings expected to improve materially in 2026 and 2027, and sentiment starting to turn, I think the shares offer a favorable risk/reward profile from here.
Have other thoughts on Kinepolis Group?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
The user Ivoed has a position in ENXTBR:KIN. Simply Wall St has no position in any of the companies mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The author of this narrative is not affiliated with, nor authorised by Simply Wall St as a sub-authorised representative. This narrative is general in nature and explores scenarios and estimates created by the author. The narrative does not reflect the opinions of Simply Wall St, and the views expressed are the opinion of the author alone, acting on their own behalf. These scenarios are not indicative of the company's future performance and are exploratory in the ideas they cover. The fair value estimates are estimations only, and does not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that the author's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
